Wednesday, March 30, 2016 1:36:25 AM
Gaithersburg, MD, March 04, 2016 – Vtesse, Inc. announced today data from a Phase 1/2 clinical trial demonstrating a reduction in the rate of Niemann-Pick Type C1 (NPC1) Disease progression from Vtesse’s lead drug candidate VTS-270. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Center for Advancing Translational Sciences, two components of the National Institutes of Health, collaborated closely with patients, patient advocacy groups and academia to initiate the drug development phase for VTS-270. Vtesse is leading the late-stage formal drug development process.
The data were presented at the 2016 World Symposium on Lysosomal Storage Disease in San Diego, California.
The announcement comes as Vtesse is in the midst of conducting its pivotal Phase 2b/3 clinical trial of VTS-270 for treatment of NPC, a progressive, irreversible, chronically debilitating – and ultimately lethal – genetic disease. Vtesse expects to enroll a total of 51 patients at approximately 20 sites (across the United States, the European Union, and other countries) in its ongoing clinical trial.
“We are encouraged by this preliminary Phase 1/2 data, showing a clear effect on severity of symptoms from Niemann-Pick Type C1 disease,” said Ben Machielse, Drs., President and Chief Executive Officer of Vtesse, Inc. “We believe this shows that VTS-270 has the potential to substantially slow down disease progression for NPC1, which supports our continuing clinical study in the hope that we can apply for regulatory approval of VTS-270 as a treatment for the patients in need.”
The Phase 1/2 clinical data from 14 patients with Niemann-Pick Type C1 showed that after 12 months and 18 months of treatment with VTS-270, disease progression as measured by the NPC Neurological Severity Score (or NSS, which looks at, among others, ambulation, fine motor ability, cognition, speech, memory and swallowing) was significantly reduced compared to data from a control group who did not receive VTS-270.
“We are highly encouraged by these findings,” said Forbes D. Porter, M.D., Ph.D., Clinical Director of the NICHD. “We also are grateful to the families who are participating in the Phase 1 study and those enrolling in the Phase 2b/3 clinical trial.”
In January, the U.S. Food and Drug Administration (FDA) granted VTS-270 Breakthrough Therapy designation status. The Breakthrough Therapy designation is granted to help accelerate development and review of drug candidates when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270
About NPC
NPC is a progressive, irreversible, chronically debilitating – and ultimately lethal – genetic disease. It is caused by a defect in lipid transportation within the cell, which leads to excessive accumulation of lipids in the brain, liver and spleen. VTS-270 has been shown to significantly reduce disease progression in animal studies and to offer preliminary indications of efficacy in the Phase 1/2 study clinical trial. For more information on Vtesse’s pivotal Phase 2b/3 clinical trial, visit www.theNPCstudy.com.
About Vtesse
Vtesse, Inc. is a rare disease company dedicated to developing drugs for patients suffering from diseases that are underserved. Vtesse is working collaboratively with the NIH and other leading academic centers to advance a pivotal clinical study of VTS-270 (a proprietary formulation of 2-hydroxypropyl-beta-cyclodextrin) to treat NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other lysosomal storage diseases (LSDs). A highly experienced management team that has been involved in the development of more than 20 approved drugs leads Vtesse. Its experienced consortium of investors, including Alexandria Real Estate Equities, Inc., Bay City Capital LLC, Lundbeckfond Ventures, New Enterprise Associates, and Pfizer Venture Investments, has committed initial funding that is expected to bring this compound through pivotal clinical trial. Vtesse is based in Gaithersburg, Maryland and is the first spin-out company from Cydan Development, Inc. For more information, visit www.vtessepharma.com.
###
Corporate Contact:
Ravi Rao, Ph.D.
ravi@vtessepharma.com
Media Contact:
Jamie Lacey-Moreira
PressComm PR, LLC
410-299-3310
jamielacey@presscommpr.com
Recent CYTH News
- Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update • Business Wire • 03/18/2024 01:05:00 PM
- Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease • Business Wire • 03/14/2024 01:34:00 PM
- Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 03/13/2024 09:04:24 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/04/2024 09:33:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:46:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:45:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:44:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:43:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:42:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:41:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:40:57 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:44:54 PM
- Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office • Business Wire • 01/29/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 11:01:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 02:50:39 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 02:48:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:28:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 01:25:09 AM
- Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc. • Business Wire • 12/27/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:15:21 PM
- Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1 • Business Wire • 12/18/2023 02:15:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 12/18/2023 11:02:37 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 11:01:44 AM
- Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 12/14/2023 09:01:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 11/30/2023 09:30:27 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM